ABOUT PALL CORPORATION

Pall Corporation provides critical filtration, separation and purification solutions to meet the demanding needs of a broad spectrum of life sciences and industrial customers around the globe.  Across 80 locations and 10,000 people worldwide, we are unified by a singular drive: to solve our customer’s biggest fluid management challenges. And in doing so advance health, safety and environmentally responsible technologies.

Pall provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, cell and gene therapies, plasma-derived proteins, vaccines and classic pharmaceuticals.  Pall’s leading-edge filtration, single-use systems, separation, purification and analytical technologies, as well as technical services in validation, assays and process optimization applicable to laboratory and pilot-scale development, play an essential role in the industry’s ability to manufacture these products. As an established global provider of analytical and purification technologies, Pall supports faster development of new drugs and vaccines around the world.

WEBINARS/EVENTS

  • Join our panel webinar and meet the authors of the recently published gene therapy Ebook: ‘Insights on Successful Gene Therapy Manufacturing and Commercialization’ downstream article.  Hear directly from the authors on various topics related to gene therapy manufacturing and commercialization, the current state of the industry and how we can continue to advance these life-changing medicines.

  • Gene therapies provide innovative options for treating patients, particularly where other traditional therapeutics have been ineffective. The industry continues to grow and mature from research to approved therapeutics. In this panel webinar series, hear directly from the authors of the eBook  "Insights on Successful Gene Therapy Manufacturing and Commercialization" on various topics related to gene therapy manufacturing and commercialization, the current state of the industry and how we can continue to advance these life-changing medicines.

  • The process of freezing biologics for storage and transport is expected to play an increasingly important role in optimizing the supply chain as markets and production sites become more diverse. As the chosen freezing method can affect both product quality and amount of product loss, it is important to fully understand this critical step in the process. In this video we discuss an end-to-end solution to fill, freeze, transport and thaw bulk drug substances.

  • Formulation and filling is a critical part of any drug manufacturing process and demands the highest levels of quality and reliability. Pall has a range of technologies and services that enables end users to carry out their operations with increased reliability and flexibility – while ensuring the product quality is designed into the manufacturing process. Using technology from the Allegro™ single-use portfolio, Pall sterilizing grade filters and Pall’s automated solutions ensure that manual interventions are minimized and increased sterility assurance is achieved.

  • The purification of vaccines and gene therapy/viral vector products is a key part of a drug manufacturing process that requires high levels of product purity and process reproducibility. Pall has a range of technologies and offers field-based support and lab-based process development services that enable end users to purify and recover their high-value products. The process strategies to improve purity and yield as well as the challenges associated the purification of viral vector process will be discussed.

  • Vaccine manufacturing is responding to challenges for increasing safety assurance and responsiveness in order to reduce the impact of pandemic such as SARS-CoV-2. Therefore, in-depth knowledge of microorganism pathogenicity leads to develop new type of vaccines such as recombinant and viral vaccines. In this presentation we will review the current main upstream vaccine production processes, considering the choice of expression system, the means by which the biological preparation is introduced into the production cell and how Pall’s flexible single-use bioreactors support rapid process development, scale-up and safeguard the quality of life-protecting vaccines and help assure compliance with cGMP.

  • In Part 2, we will review vaccine processes with examples based upon influenza vaccine, inactivated Polio vaccine and an overview of the different types of vaccine production processes from cell expansion, USP and DSP, to the formulation and filling operations to make the finished product. We will talk about vaccine production facilities, how equipment is integrated their operating principles and biological safety levels for containment. Finally, we will look at the vaccine industry today, the supply chain and globalization, and how important vaccines are in pandemic preparedness, availability, and time to market.

  • This two-part webinar will focus on vaccines and an overview of their science, technology and, manufacturing processes. In Part 1, we will focus on the timelines and organizations involved, regulatory, quality and safety testing, and the different components and activities that contribute to their development including, antigens and adjuvants. The strategies and different philosophies which facilitate process optimization and scale-up, such as QbD and how the cost of a vaccine is assessed will also be studied.

CONTACT INFORMATION

Pall

25 Harbor Park Dr.

Port Washington, NY 11050

UNITED STATES

Phone: 516-484-5400